Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.

Kun-Ho YoonJahoon KangSe Chang KwonMichael E TrautmannMarcus HompeschJohn StewartChristopher H Sorli

Published in: Diabetes, obesity & metabolism (2020)

The delayed tmax, long half-life, and low peak-to-trough ratios observed demonstrate potential for improved efficacy and dosing flexibility, with good tolerability of efpeglenatide in patients with T2D.

Keyphrases

open label
case control
human health
randomized controlled trial
double blind
clinical trial
study protocol